#accelerate#support
Germany is the founding member state of "Acquisition of the New Crown Pneumonia Tool Acceleration Plan" (ACT-A) platform and provides financial support for 600 million euros in 2020. In addition to providing and distributing drugs and diagnostics, the ACT-A platform also promotes the development and procurement of vaccines by the vaccine pillars "New Crown Pneumonia Vaccine Implementation Plan" (COVAX). Given the current vaccine limited global production, "New Crown Pneumonia Vaccine Implementation Program" is focusing on ensuring the vaccination quota of emerging developments. Developed countries can also obtain self-use vaccines.